Skip to NavigationSkip to content

Pharmafile - Sales and Marketing News

Pfizer has revealed new Phase 2 data on its 20-valent pneumococcal conjugate vaccine candidate, detailing the efficacy of the product in preventing...
Bowel cancers can avoid being caught by immunotherapy by ‘switching off’ a molecule on the surface of cells that is otherwise recognised by...
Doctors have successfully treated porphyria using an innovative ‘gene-silencing’ drug.
Janssen’s Balversa (erdafitinib) has become the first FDA-approved fibroblast growth factor receptor (FGFR) kinase inhibitor after the US agency...
Colorado-based pharma firm Clovis Oncology has said in a filing to the US Securities and Exchange Commission that it is discontinuing the phase 2...
-Gilead to lay off one fifth of sales force -Indivior shares fall by 70% after allegations of fraud -NICE turns down Astellas' Xtandi in prostate...
Novartis’ Kisqali (ribociclib) has been rejected for use on the NHS by NICE for the treatment of advanced breast cancer, the organisation has...
Gilead Sciences is preparing to lay off around a fifth of its salesforce in anticipation for the expiry of patents on two of the company’s older...
The FDA has decided to approve Amgen and UCB Pharma’s Evenity (romosozumab-aqqg) for the treatment of postmenopausal osteoporosis patients at high...
Lynparza has been awarded marketing approval by the European Commission, it has emerged, as a monotherapy for the treatment of human epidermal...
Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches